Sequenom
Sequenom is a pioneer in the field of genetic analysis, specializing in the development of innovative technology and products that aim to enhance the understanding of the human genome. The company was established in 1994 and is headquartered in San Diego, California. Sequenom's primary business focus is on prenatal care, particularly the development of non-invasive prenatal testing (NIPT) to detect chromosomal abnormalities in fetuses.
History[edit | edit source]
Sequenom was founded in 1994 by a group of scientists who were interested in exploring the potential of the human genome. The company initially focused on the development of MassARRAY technology, a high-performance DNA analysis platform. This technology was designed to provide researchers with a cost-effective and scalable method for genotyping and gene expression analysis.
In 2011, Sequenom launched the MaterniT21 PLUS test, the first commercially available non-invasive prenatal test (NIPT) for detecting chromosomal abnormalities in fetuses. This test marked a significant milestone in prenatal care, offering a safer and more accurate alternative to invasive diagnostic procedures.
Products and Services[edit | edit source]
Sequenom's product portfolio is primarily focused on prenatal care. The company's flagship product, the MaterniT21 PLUS test, uses advanced sequencing technology to analyze fetal DNA in maternal blood to detect the presence of certain chromosomal abnormalities.
In addition to the MaterniT21 PLUS test, Sequenom also offers the HerediT UNIVERSAL test, a comprehensive carrier screening test designed to identify couples at risk of passing on genetic disorders to their children.
Research and Development[edit | edit source]
Sequenom's research and development efforts are focused on the continued improvement and expansion of its product portfolio. The company is committed to advancing the field of genetic analysis and prenatal care through the development of innovative technologies and products.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
